ABCELLERA BIOLOGICS (8QQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has a cash flow conversion efficiency ratio of 0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€25.92 Million ≈ $30.31 Million USD) by net assets (€896.02 Million ≈ $1.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ABCELLERA BIOLOGICS market capitalisation for the company's overall valuation and market capitalisation.
ABCELLERA BIOLOGICS - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ABCELLERA BIOLOGICS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their cash flow conversion efficiency. Explore how high is ABCELLERA BIOLOGICS's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
-0.039x |
|
China Communications Construction Company Limited
F:CYY
|
-0.051x |
|
HSBC Holdings PLC
LSE:HSBA
|
0.002x |
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
-0.116x |
|
Energix Renewable Energies Ltd
TA:ENRG
|
0.002x |
|
Hercules Capital Inc
NYSE:HTGC
|
0.036x |
|
Huaneng Power International Inc
F:HUP1
|
0.034x |
|
China Southern Power Grid Energy Efficiency & Clean Energy Co Ltd
SHE:003035
|
0.087x |
Annual Cash Flow Conversion Efficiency for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual cash flow conversion efficiency of ABCELLERA BIOLOGICS from 2021 to 2025. View 8QQ stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €966.90 Million ≈ $1.13 Billion |
€-131.29 Million ≈ $-153.50 Million |
-0.136x | -32.10% |
| 2024-12-31 | €1.06 Billion ≈ $1.23 Billion |
€-108.56 Million ≈ $-126.91 Million |
-0.103x | -169.95% |
| 2023-12-31 | €1.15 Billion ≈ $1.35 Billion |
€-43.88 Million ≈ $-51.30 Million |
-0.038x | -116.93% |
| 2022-12-31 | €1.23 Billion ≈ $1.44 Billion |
€277.36 Million ≈ $324.26 Million |
0.225x | -5.68% |
| 2021-12-31 | €1.03 Billion ≈ $1.20 Billion |
€244.58 Million ≈ $285.94 Million |
0.238x | -- |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more